TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich, Germany, December 6, 2022 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the second closing and completion of its Series C […]
Financial
Enzyvant Announces Merger with Altavant
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonology CARY, N.C., Dec. 06, 2022 (GLOBE NEWSWIRE) — Enzyvant Therapeutics, Inc. and Altavant Sciences, Inc., both wholly owned subsidiaries of Sumitovant Biopharma Ltd., today announced a merger to form a biopharmaceutical […]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for patients with neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Alexander (Bo) Cumbo; Chief Administrative […]
Cleerly Hires Udo Hoffmann, MD, MPH as Chief Scientific Officer
Cardiovascular clinical trial expert brings AI imaging experience to lead research efforts NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced it has appointed Udo Hoffmann, MD, MPH, as chief scientific officer. In this role, Dr. Hoffmann will oversee Cleerly’s large-scale research efforts, including […]
Limflow Appoints Mike Mathias as Vice President, Commercial Operations
PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the appointment of Mike Mathias as Vice President of Commercial Operations. Mr. Mathias has spent his 30-year career successfully leading sales organizations […]
Rhythm Management Group Announces Acquisition of Equis Consulting Group
Acquisition creates one of the largest remote cardiac monitoring service providers in the nation. ROCKVILLE, Md., Dec. 5, 2022 /PRNewswire/ — Rhythm Management Group (Rhythm) has announced the acquisition of Equis Consulting Group (Equis), an Indiana-based provider of clinical and consultative remote monitoring and management services. The acquisition, which officially closed on September 30, forms the largest full-service remote […]
Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance
WARRINGTON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the NASDAQ Stock Market (“Nasdaq”) has granted Windtree an additional 180 days to regain compliance with Nasdaq’s $1.00 […]
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on December 1, 2022 that were approved by the Compensation Committee of its Board of […]
Rocket Pharmaceuticals Completes Acquisition of Renovacor
Acquisition further extends Rocket’s leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathy CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that […]
Cardior Welcomes Dr. Orly Vardeny as Permanent Guest to the Board
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced that Orly Vardeny, PharmD, MS, joins its Board of Directors as a permanent guest. Dr. Vardeny is an Associate professor of Medicine at the University of Minnesota Medical School, with […]
Recent
Merit Medical to Participate in Upcoming Investors Conferences in September
Medtronic Endurant™ stent graft system first and only to receive CE-mark for updated rupture labeling
SinglePass Device Achieves 100% Technical Success and Zero Clinically Significant Bleeding Events in Multicenter Study Published in the Journal of Vascular and Interventional Radiology
Popular
- No commented posts yet